Search alternatives:
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a step » _ step (Expand Search)
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a step » _ step (Expand Search)
-
16801
-
16802
Cell-targeted transgenic control of 5HT<sub>2A</sub>R levels in neurons and glia during the experience-dependent critical period.
Published 2024“…Two-way ANOVA with Tukey’s multiple comparison shows EB experience-dependent increase in 5HT<sub>2A</sub> receptor levels in both transgenic controls (<i>n</i> = 10 each, <i>repo-</i>Gal4<i>; p</i> = 5.38 × 10<sup>−10</sup>, <i>elav</i>-Gal4; <i>p</i> = 0.0205), a significant decrease in 5HT<sub>2A</sub> receptor levels in both RNAi conditions (<i>n</i> = 10 each, <i>repo-</i>Gal4<i>; p</i> = 4.63 × 10<sup>−10</sup>, <i>elav-</i>Gal4; <i>p</i> = 1.05 × 10<sup>−9</sup>), and a significant elevated EB response with glial <i>5HT</i><sub><i>2A</i></sub><i>R</i> OE (<i>n</i> = 10/condition, <i>p</i> = 2.36 × 10<sup>−9</sup>). …”
-
16803
-
16804
-
16805
-
16806
-
16807
-
16808
-
16809
-
16810
-
16811
Presentation_1_Risk of severe COVID-19 infection in persons with diabetes during the first and second waves in Denmark: A nationwide cohort study.pdf
Published 2022“…However, when mortality was restricted to the hospitalized population, the crude mortality fell from 26.8% to 19.6% in persons with diabetes, while only a minor decrease was seen in persons without diabetes (from 16.7% to 15.5%).…”
-
16812
-
16813
Hysteretic Spin Crossover between a Bisdithiazolyl Radical and Its Hypervalent σ-Dimer
Published 2010“…The value of σ<sub>RT</sub> for β-<b>1a</b> (near 10<sup>−4</sup> S cm<sup>−1</sup> at 0.5 GPa) initially decreases with pressure as the phase change takes place, but beyond 1.5 GPa this trend reverses, and σ<sub>RT</sub> increases in a manner which parallels the behavior of α-<b>1a</b>. …”
-
16814
Hysteretic Spin Crossover between a Bisdithiazolyl Radical and Its Hypervalent σ-Dimer
Published 2010“…The value of σ<sub>RT</sub> for β-<b>1a</b> (near 10<sup>−4</sup> S cm<sup>−1</sup> at 0.5 GPa) initially decreases with pressure as the phase change takes place, but beyond 1.5 GPa this trend reverses, and σ<sub>RT</sub> increases in a manner which parallels the behavior of α-<b>1a</b>. …”
-
16815
Hysteretic Spin Crossover between a Bisdithiazolyl Radical and Its Hypervalent σ-Dimer
Published 2010“…The value of σ<sub>RT</sub> for β-<b>1a</b> (near 10<sup>−4</sup> S cm<sup>−1</sup> at 0.5 GPa) initially decreases with pressure as the phase change takes place, but beyond 1.5 GPa this trend reverses, and σ<sub>RT</sub> increases in a manner which parallels the behavior of α-<b>1a</b>. …”
-
16816
Hysteretic Spin Crossover between a Bisdithiazolyl Radical and Its Hypervalent σ-Dimer
Published 2010“…The value of σ<sub>RT</sub> for β-<b>1a</b> (near 10<sup>−4</sup> S cm<sup>−1</sup> at 0.5 GPa) initially decreases with pressure as the phase change takes place, but beyond 1.5 GPa this trend reverses, and σ<sub>RT</sub> increases in a manner which parallels the behavior of α-<b>1a</b>. …”
-
16817
Hysteretic Spin Crossover between a Bisdithiazolyl Radical and Its Hypervalent σ-Dimer
Published 2010“…The value of σ<sub>RT</sub> for β-<b>1a</b> (near 10<sup>−4</sup> S cm<sup>−1</sup> at 0.5 GPa) initially decreases with pressure as the phase change takes place, but beyond 1.5 GPa this trend reverses, and σ<sub>RT</sub> increases in a manner which parallels the behavior of α-<b>1a</b>. …”
-
16818
Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial
Published 2016“…Secondary endpoints: Prednisolone-treatment decreased immune activation (sCD14, suPAR, CD38/HLA-DR/CD8+) and increased CD4-counts (+77.42 ± 5.70 cells/μl compared to -37.42 ± 10.77 cells/μl under placebo, p < 0.0001). …”
-
16819
-
16820